Financial Instruments, Risk Management and Fair Value measurements (Tables)

12 Months Ended

Dec. 31, 2017

The following information is presented for assets and liabilities that are recorded in the consolidated balance sheets at fair value measured on a recurring basis. There were no assets recorded at fair value measured on a recurring basis as of December 31, 2016. There were no significant transfers of assets and liabilities that are recorded at fair value between Level 1 and Level 2 during the period reported.



In millions	Level 1⁽¹⁾		Level 2⁽²⁾		Level 3⁽³⁾		Total
December 31, 2017
Assets:
Equity securities ⁽⁴⁾	$	1.8	$	—	$	—	$	1.8
Total assets	$	1.8	$	—	$	—	1.8
Liabilities:							—
Deferred compensation arrangement ⁽⁵⁾	$	2.0	$	—	$	—	$	2.0
Separation-related Reimbursement Awards ⁽⁶⁾⁽⁷⁾	0.9		—		—		0.9
Total liabilities	$	2.9	$	—	$	—	$	2.9



In millions	Level 1⁽¹⁾		Level 2⁽²⁾		Level 3⁽³⁾		Total
December 31, 2016
Liabilities:							—
Deferred compensation arrangement ⁽⁵⁾	$	0.7	$	—	$	—	$	0.7
Separation-related Reimbursement Awards ⁽⁶⁾⁽⁷⁾	2.1		—		—		2.1
Total liabilities	$	2.8	$	—	$	—	$	2.8

__________


(1)	Quoted prices in active markets for identical assets.


(2)	Quoted prices for similar assets and liabilities in active markets.


(3)	Significant unobservable inputs.


(4)	Included within "Prepaid and other current assets" on the consolidated balance sheet.


(5)	Included within "Other liabilities" on the consolidated balance sheet.


(6)	Included within "Accrued expenses" on the consolidated balance sheet.

(7)

This amount represents an amount due to WestRock associated with WestRock equity awards held by Ingevity employees post Separation. In accordance with the Employee Matters Agreement between Ingevity and WestRock entered into in connection with the Separation, we are required to reimburse WestRock the fair market value of awards on the day Ingevity employees exercise their awards. The expense recognized during the years ended December 31, 2017 and 2016 was $0.3 million and $1.6 million, respectively.